Previous studies have reported that first- and second-generation EGFR TKIs have poor penetration across the blood–brain barrier, with the percentage of drug penetration ranging between 0.7% and 1.3%, which may permit tumor growth in the central nervous system (9). The gene discussed is EGFR; the disease is neoplasm.